CL-J has received research support from AstraZeneca, Lundbeck, and Wyeth; and has participated in speakers/advisory boards for Abbott, AstraZeneca, GlaxoSmithKline, and Janssen. EV is a consultant to Almirall, AstraZeneca, Bial, Bristol-Myers Squibb, Eli Lilly & Co., Forest, GlaxoSmithKline, Janssen, Jazz, Lundbeck, Merck Sharp & Dohme, Novartis, Organon, Pfizer, Sanofi-aventis, Servier, Schering-Plough, UBC, and Wyeth; has received honoraria from Janssen; and has participated in speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Janssen, Pfizer, and Servier. JL-V, AG, JO-D, VB, CT and AM-A have no conflicts of interest to report.
Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence
Version of Record online: 16 AUG 2010
© 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S
Volume 12, Issue 5, pages 557–567, August 2010
How to Cite
López-Jaramillo, C., Lopera-Vásquez, J., Gallo, A., Ospina-Duque, J., Bell, V., Torrent, C., Martínez-Arán, A. and Vieta, E. (2010), Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disorders, 12: 557–567. doi: 10.1111/j.1399-5618.2010.00835.x
- Issue online: 16 AUG 2010
- Version of Record online: 16 AUG 2010
- Received 6 May 2009, revised and accepted for publication 14 April 2010
- bipolar I disorder;
- cognitive function;
- manic episode;
López-Jaramillo C, Lopera-Vásquez J, Gallo A, Ospina-Duque J, Bell V, Torrent C, Martínez-Arán A, Vieta E. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010: 12: 557–567. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.
Objective: To determine if the repeated occurrence of manic episodes in bipolar I disorder (BD-I) patients is associated with reduced cognitive performance, which could in turn imply a worsening in the disorder’s evolution.
Method: Cognitive performance in euthymic patients was assessed using attention, memory, and executive function tests on 24 BD-I patients who had experienced only 1 manic episode, on 27 BD-I patients with 2 manic episodes, on 47 BD-I patients with 3 or more manic episodes, and on 66 healthy control subjects.
Results: In BD-I patients, number of manic episodes was positively associated with poorer performance on neurocognitive tests, an association that was not accounted for by depression, disease chronicity, onset, or medication. Significant differences in attention and executive function were found between patients and controls and in those patients who had had just 1 manic episode compared to those who had 3 or more.
Conclusion: The number of manic episodes predicted poor cognitive performance, suggesting that the recurrence of mania may have a long-term neuropsychological impact. Prospective follow-up studies need to be completed to explore this effect further as better treatment adherence may have a protective effect on neurocognitive function.